{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T20:58:40Z","timestamp":1772744320826,"version":"3.50.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.clgc.2024.102143","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:18:03Z","timestamp":1719274683000},"page":"102143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer"],"prefix":"10.1016","volume":"22","author":[{"suffix":"IV","given":"William Paul","family":"Skelton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5853-9697","authenticated-orcid":false,"given":"Jack","family":"Masur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7885-2009","authenticated-orcid":false,"given":"Parvaneh","family":"Fallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Praful","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlene","family":"Mantia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley Alexander","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5618-8079","authenticated-orcid":false,"given":"Pier Vitale","family":"Nuzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0594-7976","authenticated-orcid":false,"given":"Elio","family":"Adib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4507-2396","authenticated-orcid":false,"given":"Talal El","family":"Zarif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Preston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0616-6840","authenticated-orcid":false,"given":"Timothy Nguyen","family":"Clinton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1274-7200","authenticated-orcid":false,"given":"Roger","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graeme S.","family":"Steele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wassim","family":"Kassouf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dory","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Russell","family":"Pond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7571-3548","authenticated-orcid":false,"given":"Rakesh K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1010-9611","authenticated-orcid":false,"given":"Guru P.","family":"Sonpavde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clgc.2024.102143_bib0001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.clgc.2024.102143_bib0002","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.clgc.2024.102143_bib0003","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.clgc.2024.102143_bib0004","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.eururo.2012.05.048","article-title":"A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer","volume":"62","author":"Meeks","year":"2012","journal-title":"Eur Urol"},{"issue":"9373","key":"10.1016\/j.clgc.2024.102143_bib0005","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(03)13580-5","article-title":"Advanced bladder cancer meta-analysis collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis","volume":"361","year":"2003","journal-title":"Lancet"},{"issue":"6 Pt 1","key":"10.1016\/j.clgc.2024.102143_bib0006","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1016\/j.juro.2006.08.004","article-title":"Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the bladder cancer research consortium","volume":"176","author":"Shariat","year":"2006","journal-title":"J Urol"},{"issue":"16","key":"10.1016\/j.clgc.2024.102143_bib0007","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","volume":"29","author":"Trialists","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4 Pt 1","key":"10.1016\/j.clgc.2024.102143_bib0008","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.juro.2015.10.133","article-title":"Final pathological stage after neoadjuvant chemotherapy and radical cystectomy for bladder cancer-does pT0 predict better survival than pTa\/Tis\/T1?","volume":"195","author":"Zargar","year":"2016","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.clgc.2024.102143_bib0009","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.eururo.2014.09.007","article-title":"Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"67","author":"Zargar","year":"2015","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.clgc.2024.102143_bib0010","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2013.06.049","article-title":"Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis","volume":"65","author":"Petrelli","year":"2014","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102143_bib0011","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/bju.15434","article-title":"Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration","volume":"128","author":"Ravi","year":"2021","journal-title":"BJU Int"},{"issue":"11","key":"10.1016\/j.clgc.2024.102143_bib0012","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1001\/jamaoncol.2018.3542","article-title":"Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle-invasive bladder cancer","volume":"4","author":"Peyton","year":"2018","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2024.102143_bib0013","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1002\/cncr.23848","article-title":"A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience","volume":"113","author":"Dash","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2024.102143_bib0014","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1038\/ncomms3516","article-title":"Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels","volume":"4","author":"Chauhan","year":"2013","journal-title":"Nat Commun"},{"issue":"9123","key":"10.1016\/j.clgc.2024.102143_bib0015","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0140-6736(98)03228-0","article-title":"Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?","volume":"352","author":"Lever","year":"1998","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clgc.2024.102143_bib0016","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.clgc.2021.04.002","article-title":"Angiotensin Blockade Modulates the Activity of PD1\/L1 inhibitors in metastatic urothelial carcinoma","volume":"19","author":"Jain","year":"2021","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"10.1016\/j.clgc.2024.102143_bib0017","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/sj.bjc.6605955","article-title":"Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine","volume":"103","author":"Nakai","year":"2010","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.clgc.2024.102143_bib0018","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1073\/pnas.1818357116","article-title":"Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma","volume":"116","author":"Zhao","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.clgc.2024.102143_bib0019","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.clgc.2022.04.012","article-title":"Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors","volume":"20","author":"Nuzzo","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"10","key":"10.1016\/j.clgc.2024.102143_bib0020","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00432-009-0587-3","article-title":"Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy","volume":"135","author":"Wilop","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7","key":"10.1016\/j.clgc.2024.102143_bib0021","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","article-title":"Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial","volume":"5","author":"Murphy","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2024.102143_bib0022","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.12.024","article-title":"Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors","volume":"163","author":"Drobni","year":"2022","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.clgc.2024.102143_bib0023","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3892\/mco.2015.630","article-title":"Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients","volume":"3","author":"Osumi","year":"2015","journal-title":"Mol Clin Oncol"},{"issue":"11","key":"10.1016\/j.clgc.2024.102143_bib0024","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nrc2945","article-title":"The renin-angiotensin system and cancer: old dog, new tricks","volume":"10","author":"George","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"10.1016\/j.clgc.2024.102143_bib0025","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1002\/ijc.29609","article-title":"Matrix-assisted laser desorption\/ionisation (MALDI) TOF analysis identifies serum angiotensin II concentrations as a strong predictor of all-cause and breast cancer (BCa)-specific mortality following breast surgery","volume":"137","author":"Boccardo","year":"2015","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2024.102143_bib0026","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data","volume":"48","author":"Vale","year":"2005","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.clgc.2024.102143_bib0027","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.clgc.2024.102143_bib0028","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1464-410X.2010.09912.x","article-title":"Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience","volume":"108","author":"Yafi","year":"2011","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.clgc.2024.102143_bib0029","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.clgc.2024.102143_bib0030","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1002\/cncr.24466","article-title":"Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy","volume":"115","author":"Sonpavde","year":"2009","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.clgc.2024.102143_bib0031","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.eururo.2011.12.010","article-title":"Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer","volume":"61","author":"Rosenblatt","year":"2012","journal-title":"Eur Urol"},{"issue":"410","key":"10.1016\/j.clgc.2024.102143_bib0032","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan5616","article-title":"Targeting the renin-angiotensin system to improve cancer treatment: implications for immunotherapy","volume":"9","author":"Pinter","year":"2017","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.clgc.2024.102143_bib0033","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022129","article-title":"Non-smad signaling pathways of the TGF-beta family","volume":"9","author":"Zhang","year":"2017","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"11","key":"10.1016\/j.clgc.2024.102143_bib0034","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2217\/imt.12.112","article-title":"Cancer-associated fibroblasts as targets for immunotherapy","volume":"4","author":"Kakarla","year":"2012","journal-title":"Immunotherapy"},{"issue":"9","key":"10.1016\/j.clgc.2024.102143_bib0035","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/carcin\/bgn171","article-title":"The renin-angiotensin system and malignancy","volume":"29","author":"Ager","year":"2008","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.clgc.2024.102143_bib0036","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1172\/JCI16645","article-title":"Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth","volume":"112","author":"Egami","year":"2003","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.clgc.2024.102143_bib0037","doi-asserted-by":"crossref","first-page":"18640","DOI":"10.18632\/oncotarget.15553","article-title":"The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma","volume":"8","author":"Coulson","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.clgc.2024.102143_bib0038","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2219199120","article-title":"Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models","volume":"120","author":"Datta","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.clgc.2024.102143_bib0039","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000337979","article-title":"How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy?","volume":"83","author":"Kim","year":"2012","journal-title":"Oncology"},{"key":"10.1016\/j.clgc.2024.102143_bib0040","doi-asserted-by":"crossref","first-page":"21359","DOI":"10.1038\/srep21359","article-title":"Impact of angiotensin I-converting enzyme inhibitors and angiotensin II type-1 receptor blockers on survival of patients with NSCLC","volume":"6","author":"Miao","year":"2016","journal-title":"Sci Rep"},{"issue":"13","key":"10.1016\/j.clgc.2024.102143_bib0041","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/j.ejca.2011.04.019","article-title":"Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination","volume":"47","author":"Keizman","year":"2011","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.clgc.2024.102143_bib0042","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/annonc\/mdv147","article-title":"Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma","volume":"26","author":"Izzedine","year":"2015","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.clgc.2024.102143_bib0043","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1158\/1078-0432.CCR-14-2332","article-title":"Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma","volume":"21","author":"McKay","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.clgc.2024.102143_bib0044","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11060-017-2528-3","article-title":"Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and\/or bevacizumab","volume":"134","author":"Levin","year":"2017","journal-title":"J Neurooncol"},{"issue":"12","key":"10.1016\/j.clgc.2024.102143_bib0045","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1245\/s10434-012-2568-z","article-title":"Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancer","volume":"19","author":"Yuge","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2024.102143_bib0046","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1046\/j.1442-2042.2001.00347.x","article-title":"Progression of prostate cancer to neuroendocrine cell tumor","volume":"8","author":"Tanaka","year":"2001","journal-title":"Int J Urol"},{"issue":"11","key":"10.1016\/j.clgc.2024.102143_bib0047","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1158\/1535-7163.MCT-10-0535","article-title":"Cis-dichlorodiammineplatinum upregulates angiotensin II type 1 receptors through reactive oxygen species generation and enhances VEGF production in bladder cancer","volume":"9","author":"Tanaka","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.clgc.2024.102143_bib0048","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1245\/s10434-016-5534-3","article-title":"Prognostic impact of renin-angiotensin inhibitors in patients with bladder cancer undergoing radical cystectomy","volume":"24","author":"Yoshida","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102143_bib0049","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.juro.2015.05.104","article-title":"Renin-angiotensin inhibitors decrease recurrence after transurethral resection of bladder tumor in patients with nonmuscle invasive bladder cancer","volume":"194","author":"Blute","year":"2015","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.clgc.2024.102143_bib0050","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/bjc.2011.565","article-title":"Prognonstic impact of renin-angiotensin system blockade in localised upper-tract urothelial carcinoma","volume":"106","author":"Tanaka","year":"2012","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2024.102143_bib0051","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2174\/157488709788185996","article-title":"Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in urogenital cancer","volume":"4","author":"Miyajima","year":"2009","journal-title":"Rev Recent Clin Trials"},{"issue":"1","key":"10.1016\/j.clgc.2024.102143_bib0052","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-0774.2007.00025.x","article-title":"Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer","volume":"20","author":"Kosugi","year":"2007","journal-title":"Hum Cell"},{"issue":"4","key":"10.1016\/j.clgc.2024.102143_bib0053","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.urology.2010.11.002","article-title":"Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer","volume":"77","author":"Shirotake","year":"2011","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.clgc.2024.102143_bib0054","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1158\/1055-9965.EPI-05-0934","article-title":"The angiotensin II\/angiotensin II receptor system correlates with nodal spread in intestinal type gastric cancer","volume":"16","author":"R\u00f6cken","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"10.1016\/j.clgc.2024.102143_bib0055","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.bjc.6602961","article-title":"Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival","volume":"94","author":"Ino","year":"2006","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.clgc.2024.102143_bib0056","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1007\/s13277-015-3235-3","article-title":"Association between AT1 and AT2 angiotensin II receptor expression with cell proliferation and angiogenesis in operable breast cancer","volume":"36","author":"Arrieta","year":"2015","journal-title":"Tumour Biol"},{"issue":"19","key":"10.1016\/j.clgc.2024.102143_bib0057","first-page":"4089","article-title":"Local bone marrow renin-angiotensin system in the genesis of leukemia and other malignancies","volume":"20","author":"Haznedaroglu","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T06:57:09Z","timestamp":1738565829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324001149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1558767324001149"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102143","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102143","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102143"}}